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Prairie View A&M University 
Prairie View, TX 77445 
Dear Dr. Owens: 
The attached bulletin from the Food 
and Drug Administration Is sent to you for 
your information. 
Very truly yours, 
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Papaverine and Ethaverine Studies 
The effectiveness of products containing papaverine 
(Pavabid, Cerespan, Therapav, Pava Time-cap, and 
others) and ethaverine (Isovex-100, Ethaquin, Ethatab, 
Cebral, and others) has recently been challenged by an 
FDA advisory committee. 
FDA's Peripheral and Central Nervous System Drugs 
Advisory Committee unanimously concluded in August 
that "there is no body of evidence that will support the ef­
fectiveness of papaverine and ethaverine for any of their 
claimed indications." 
The two drugs, which are chemically closely related, 
have been on the market approximately 40 years in 
various dosage forms. They are prescribed for cerebrovas­
cular, cardiovascular, and peripheral vascular problems, 
primarily in elderly patients. However, they had never 
been evaluated in accordance with the provision of the 
Federal Food, Drug, and Cosmetic Act that requires ade­
quate and well-controlled studies demonstrating effec­
tiveness. 
After reviewing studies submitted by several manufac­
turers, the Advisory Committee concluded that, although 
papaverine and ethaverine may act as vasodilators in 
animals and normal human subjects, the studies do not 
show that the drugs are effective for the disease states for 
which they are presently labeled. 
Other data from a study carried out by the University 
of Tennessee for FDA's Division of Biopharmaceutics 
showed poor bioavailability for the time release 
papaverine-containing products. In addition, previous 
independent studies indicated that papaverine has a 
biological half life of only one to two hours. Approx­
imately 70 percent of an orally administered dose is 
metabolized in the liver before reaching the circulatory 
system, so that under the best of conditions only 30 per­
cent of a dose can reach the appropriate site, and even 
that is removed quite rapidly. 
The Drug Bulletin will keep health professionals in­
formed of any additional evaluations and actions regard­
ing these drugs. 
FDA Begins Proceedings To Remove 
Erythromycin Estolate From Market 
FDA's Bureau of Drugs is initiating formal administra­
tive procedures to remove solid dosage forms of erythro­
mycin estolate (Ilosone) from the market due to a greater 
risk of hepatotoxicity than that associated with other 
forms of erythromycin.1-4 Still under consideration are 
the liquid pediatric dosage forms. 
Erythromycin estolate labeling has carried a warning 
of the drug's hepatotoxicity since 1962. A stronger boxed 
warning was added in 1973, as reported in the January 
1974 Drug Bulletin. 
History of Problem 
The question of removal of the drug from the market 
was considered by FDA's Anti-Infective Agents Advisory 
Committee in 1973. The Committee recommended that 
erythromycin estolate continue to be allowed on the 
market because there was a suggestion that the greater 
risk of hepatotoxicity with this drug might be outweighed 
by a therapeutic superiority over other erythromycin 
products by virtue of the higher blood levels it produced. 
More recent data indicate, however, that the estolate 
does not, in fact, produce higher blood levels of active 
erythromycin. 
Previous blood level studies had measured erythromy­
cin estolate in the blood. The active fraction, however, is 
the free erythromycin base. Bioavailability studies re­
cently carried out for FDA at the University of Texas, us­
ing a method which differentiated the free base from the 
inactive esters, showed that after single-dose administra­
tion of erythromycin estolate and erythromycin stearate 
the blood concentration of free base from the estolate 
product was only 45 percent of that noted from the stea­
rate product. In a multiple-dose comparison of erythro­
mycin estolate with erythromycin base (5 doses given six 
hours apart), after the first dose the blood concentration 
of free erythromycin from the estolate was only 36 per­
cent of that from the erythromycin base product. With 
the fifth dose the concentration from the estolate had in­
creased to 88 percent, but the cumulative concentration 
for all five doses was only 69 percent of that achieved with 
the erythromycin base product. 
Several clinical studies fail to support increased effec­
tiveness of erythromycin estolate in comparison with 
other erythromycin products, •>* and authors of review ar­
ticles concur.3-4 
Adverse Reaction Data 
FDA adverse reaction data from 1969 through 1978 in­
clude 418 reports of hepatotoxicity due to specified oral 
erythromycin products. The data show 93 percent of the 
hepatotoxicity occurred in patients receiving erythromy­
cin estolate, and among these for which age was speci­
fied, 82 percent of the reactions occurred in patients 
12-years-old and older. 
Because of the substantially higher rate of hepatic 
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reactions with erythromycin estolate in comparison with 
other forms of erythromycin, and because the estolate ap­
pears to offer no compensating benefits, FDA's Bureau of 
Drugs is moving to remove solid dosage forms of erythro­
mycin estolate from the market on safety grounds. Re­
view is continuing on whether, in young children, eryth­
romycin estolate is sufficiently low in toxic effects and has 
certain special advantages that would warrant its remain­
ing on the market. The Drug Bulletin will keep health 
professionals informed about further developments. This 
action does not affect the safer oral erythromycin prod­
ucts containing erythromycin base, erythromycin stea-
rate, or erythromycin ethylsuccinate. 
References: 
1. Brown, ST, et al: Comparison of erythromycin base and estolate in 
gonococcal urethritis, JAMA 238 (13): 1371-3, 1977. 
2. Billow, BW, et al: A clinical study of ery thromycin: a comparative 
evaluation of several salts. Curr Ther Res 6: 381-4, 1964. 
3. Ginsburg, CM. and Eichenwald, HF: Erythromycin: a review of its 
uses in pediatric practice. J Pediatr 89 (6): 872-84, 1976. 
4. Eichenwald, HF, and McCracken, Jr., GH: Antimicrobial therapy 
in infants and children. Part I. Review of antimicrobial agents/ Pediatr 
93: 337-56, 1978. 
Dantrolene Sodium Approved 
for Malignant Hyperthermia 
FDA has approved intravenous dantrolene sodium 
(Dantrium) for treatment of malignant hyperthermia 
syndrome, a rare genetically determined condition 
precipitated by inhalants and neuromuscular blocking 
agents used during general anesthesia and by other 
stressful situations. Previously, no specific drug product 
was commercially available to treat this condition which 
had a mortality rate of 50 to 70 percent.'>2 
Intravenous dantrolene sodium is a new formulation of 
the product which has for some time been approved in 
oral form for use as a direct muscle relaxant in controll­
ing the manifestations of clinical spasticity resulting from 
upper motor neuron disorders. 
During malignant hyperthermia, skeletal muscle un­
dergoes contraction as a result of release of calcium from 
the sarcoplasmic reticulum in response to drugs or stress. 
It is postulated that dantrolene might decrease the 
amount of transmitter released by the excitation-contrac­
tion coupling process and thus indirectly reduce the 
amount of calcium released, resulting in a reversal or 
decrease of the manifestations of the hyperthermic crisis. 
Signs of Malignant Hyperthermia 
Primary signs of malignant hyperthermia include: 
tachycardia, tachypnea, increased arteriovenous oxygen 
difference with systemic arterial hypoxia, hypercarbia, 
and metabolic acidosis. Other signs which may be present 
are: cardiac arrhythmias, cyanosis, skin mottling, fever, 
rigidity, profuse sweating, unstable blood pressure, 
hyperkalemia, myoglobinemia, and elevated creatine 
phosphokinase (CPK). Fever is not always present early in 
the syndrome and it may be absent altogether. 
Malignant hyperthermia is a condition which is now 
diagnosed more frequently than previously, and which 
manifests itself at various levels of severity. The first sign 
of the condition may be the too rapid heating of the car­
bon dioxide canister on the anesthesia machine. The con­
dition may develop unexpectedly, even in patients with a 
past history of several uneventful anesthetic administra­
tions, but it is most frequently encountered in individuals 
with a family history suggestive of similar events. 
Known Supportive Measures Necessary 
Intravenous dantrolene sodium should be administered 
as soon as the malignant hyperthermia reaction is 
recognized. However, it is not a substitute for known sup­
portive measures, which continue to be necessary. These 
include, in most cases, discontinuing the suspected trig­
gering agents, attending to the increased oxygen require­
ments, managing the metabolic acidosis, instituting cool­
ing when necessary, assuring adequate urinary output, 
and monitoring for electrolyte imbalance. 
After studies in susceptible experimental animals, 
which established that intravenous dantrolene reduced 
the mortality and alleviated the signs of malignant hyper­
thermic crisis,3 the drug product was widely distributed 
to clinical investigators in the United States, Canada, and 
other countries for use in emergencies and for standby in 
susceptible individuals. The clinical data established that 
intravenous dantrolene is effective in alleviating the signs 
of malignant hyperthermic crisis in humans, just as it is in 
susceptible animals. All patients who were treated early 
in the crisis recovered when intravenous dantrolene so­
dium was used along with intensive supportive treatment. 
Until an adequate supply can be assured through regu­
lar marketing channels, the manufacturer of Dantrium, 
Norwich-Eaton, has established a hotline for emergency 
requests for specific patients believed to be susceptible to 
malignant hyperthermia. The number is (607) 335-2133. 
References: 
1. Britt, BA, and Kalow, W: Malignant hyperthermia; a statistical 
review. Canad Anaesth Soc J, 17: 293-315, 1970. 
2. Britt, BA; et al: Chapter 5 of Malignant Hyperthermia, Current 
Concepts, ed. bv E. O. Henschel, pp. 63-67, Appleton-Century-Crofts, 
N.Y., 1977. 
3. Gronert, GA; Milde JH; Theye. RA: Dantrolene in porcine malig­
nant hyperthermia. Anesthesiology 44 (6): 488-95, 1976. 
Problems with B12 
Radiodilution Assays 
Physicians, laboratory personnel, and other health 
professionals should be aware that commercial radiodilu­
tion assays may not provide an accurate measure of 
vitamin BI2 (cobalamin) serum levels. 
FDA recently convened the Clinical Chemistry and 
Hematology Devices Panel to discuss reports that the 
assays are not specific for vitamin B12. These reports have 
indicated that BI2 analogs were being measured as true 
B,2> resulting in falsely elevated serum Bi2 measurements 
that could mask vitamin B12 deficiency. 
This would result in approximately 20 percent of pa­
tients with B12 deficiency not being diagnosed if clinicians 
relied upon only the results of the assays. Failure to 
diagnose and treat a BI2 deficiency can result in irrepara­
ble neurologic damage. Vitamin B12 deficiency is also 
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related to macrocytic anemia, pernicious anemia, and 
megaloblastic anemia. 
Reasons for Lack of Specificity 
The lack of specificity was due to the B]2 binding pro­
tein used. Intrinsic factor binds only B12; R protein binds 
both B12 and B12 analogs. The 10 assays studied employ 
mixtures of R protein and intrinsic factor, with R protein 
content ranging from 51 percent to 85 percent. An addi­
tional difficulty is that intrinsic factor loses 10 percent of 
its B12 binding capacity at a pH of 4.0 and greater than 
98 percent at pH 2.0. Five commercial assays were car­
ried out at a pH of 2.0 or less and therefore any intrinsic 
factor present was essentially eliminated. 
Acting upon the panel's recommendations after a 
review of the data, the Agency contacted manufacturers 
of B12 radiodilution assays and requested that they im­
mediately evaluate their products for the potential er­
roneous results and subsequent misdiagnoses. FDA asked 
the manufacturers to notify it of the results of the evalua­
tions and of the need for product modification and/or 
labeling revision. FDA also asked the manufacturers to 
provide their customers with information sufficient for 
the safe and effective use of the assays. The manufac­
turers have informed their customers of the potential 
problems with their assays and several manufacturers 
have modified their product. 
Task Force Established 
In addition, FDA has requested that the National 
Committee for Clinical Laboratory Standards (NCCLS) 
establish a task force to develop a voluntary standard for 
vitamin B12 radiodilution assays. A preliminary draft of 
the NCCLS standard was reviewed favorably by the 
Panel. 
FDA requests that physicians, laboratory personnel, 
and other health professionals report any difficulties with 
radiodilution assays for vitamin B12 to Kaiser Aziz, 
Ph.D., Bureau of Medical Devices, Food and Drug Ad­
ministration, HFK-440, 8757 Georgia Avenue, Silver 
Spring, MD 20910; phone (310) 427-7550. 
Reports of Injuries 
FDA's Bureau of Radiological Health has received re­
ports of more than 460 injuries in the past four years. 
Most of the patients in these cases complained of con­
siderable pain and eye discomfort. A diffuse punctate 
keratitis involving the cornea is the most prominent 
clinical finding in such cases. Skin erythema is the other 
major clinical finding. Increased sensitivity to this radia­
tion is likely in individuals who are sensitive to sunlight or 
who are on medication such as tetracyline which could 
make them photosensitive. Bioeffects studies, including 
epidemiological studies of human populations, also in­
dicate possible long-term effects of ultraviolet (UV) 
radiation, such as premature skin-aging and malignant 
skin tumors as a result of prolonged or repeated 
exposure.' 
Injuries occur when the protective outer glass bulb of 
these lamps is broken, permitting an exposure to short­
wave UV radiation. Most such injuries occur following 
continuous exposure for several hours at a distance of up 
to six meters from the damaged lamp. These lamps can 
continue to operate and emit hazardous UV radiation for 
many days. 
Performance Standard 
To promote the safety of mercury vapor lamps, FDA 
has developed an equipment performance standard. 
Manufacturers of lamps sold for use in areas where in­
dividuals may be exposed to lamps for extended periods 
must provide an automatic mechanism to shut off the 
lamp in case the outer bulb is damaged. Labeling for 
these lamps should state: 
This lamp should self-extinguish within 15 min­
utes after the outer envelope is broken or punctured. 
If such damage occurs, TURN OFF AND REMOVE 
LAMP to avoid possible injury from hazardous short­
wave ultraviolet radiation. 
Reference: 
1. Kolhouse, JF; Kondo, H; Allen, NC, el al: Cobalamin analogues 
are present in human plasma and can mask cobalamin deficiency 
because current radioisotope dilution assays are not specific for true 
cobalamin, N Engl J Med 299: 785-792, 1978. 
Manufacturers of lamps sold for uses where injury from a 
broken lamp is unlikely may avoid incorporating a shut 
off, but must clearly state such restricted use in all label­
ing and advertising. For lamps that do not shut off 
automatically, the labeling should state: 
New Standards Established 
For Mercury Vapor Lamps 
A mandatory safety performance standard for mercury 
vapor lamps has been established by FDA. 
Over 25 million high-intensity mercury vapor dis­
charge lamps are presently in use in the United States. 
These lamps are used for roadway lighting, sports arenas, 
school gymnasiums, parking areas, warehouses, and 
retail establishments, as well as home use to light yards, 
patios, and driveways. 
WARNING: 
This lamp can cause serious skin burn and eye in­
flammation from shortwave UV radiation if outer 
envelope of the lamp is broken or punctured. Do not 
use where people will remain for more than a few 
minutes unless adequate shielding or other safety 
precautions are used. Lamps that will automatically 
extinguish when the outer envelope is broken or 
punctured are commercially available. 
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.The safety standard applies to lamps manufactured 
after March 6, 1980. 
This new standard is designed to permit the continued 
use of vapor lamps while providing adequate protection 
to the public if the outer bulbs are damaged. 
Medical Treatment Needed 
The Agency recommends that individuals exposed to 
UV radiation from a damaged lamp should see a physi­
cian if symptoms of skin burns or eye irritation occur. In­
dividuals using mercury vapor or metal halide lamps in a 
home or yard should consider replacing them with those 
that have a safety shut-off feature. An alternative is to in­
stall a UV radiation-absorbing shield over the lamp 
reflector. 
Physicians who treat patients with keratitis and/or 
erythema for which some doubt exists about the cause 
should inquire about possible exposure to these high-in­
tensity lamps. FDA would appreciate receiving reports of 
injury when potential exposure has been confirmed. Send 
reports to: 
Division of Biological Effects, HFX-140 
Bureau of Radiological Health 
Food and Drug Administration 
5600 Fishers Lane 
Rockville, MD 20857 
Reference: 
i. Federal Register, Vol. 43. No. 78. Friday. April 21, 1978. 
Carbidopa Available 
As Single Agent 
Physicians treating patients with idiopathic Parkinson's 
disease, postencephalitic parkinsonism, and symptomatic 
parkinsonism should be aware that carbidopa (Lodosyn) 
is now available as a single agent from Merck, Sharp and 
Dohme. 
Carbidopa can be used in combination with levodopa 
or with levodopa/carbidopa combinations (Sinemet) to 
lessen the side effects of levodopa and, in some patients, 
to achieve greater effectiveness or a smoother therapeutic 
response. 
Carbidopa can be used to augment the levodopa/car­
bidopa preparation or with levodopa alone, in patients 
who require a ratio other than the 1:10 carbidopa to 
levodopa present in Sinemet. It is also useful for patients 
who need to be titrated on the individual ingredients 
before being given the combination, and for those who 
need only low doses of levodopa and do not, therefore, 
receive enough carbidopa when given the combination. 
Carbidopa is a dopa decarboxylase inhibitor. When 
administered with levodopa, carbidopa decreases the 
dosage requirement of levodopa by at least 75 percent 
and reduces the incidence of certain side effects 
associated with high-dosage levodopa therapy, such as 
anorexia, nausea, and vomiting. In addition, there is sug­
gestive evidence that it may provide some protection 
against levodopa-induced cardiac arrhythmias. 
Although Merck, Sharp and Dohme is not yet market­
ing carbidopa alone, FDA approved its use in 1977 and 
it is available to physicians from the manufacturer upon 
request. 
Clinoril Adverse Reactions 
Numerous adverse reaction reports received by FDA 
indicate that sulindac (Clinoril) has side effects similar to 
those of indomethacin (Indocin). This might be expected 
since sulindac is an isostere of indomethacin. 
A nonsteroidal, anti-inflammatory agent, sulindac has 
received widespread use since it was First marketed in 
November 1978. FDA has received reports of the follow­
ing adverse reactions to sulindac: congestive heart 
failure, Stevens-Johnson syndrome, toxic epidermal 
necrolysis, bone marrow depression, thrombocytopenia, 
leukopenia, gastrointestinal perforation, nephropathy, 
and pancreatitis. Reported adverse ocular effects in­
clude: diplopia, cloudy vision, eyeball swelling, nonin­
flammatory ulceration of the cornea, retinal hemor­
rhage, blurred vision, and spots before the eyes. 
The majority of these effects have also been reported in 
association with use of other nonsteroidal anti-inflamma­
tory drugs, but most of them are not yet mentioned in the 
present labeling of sulindac. 
FDA is currently analyzing data to identify factors 
which may predispose patients to risk of these reactions. 
Physicians and other health professionals who note 
adverse reactions to the drug should report them to: 
Division of Epidemiology and 
Drug Experience (HDF-210) 
Food and Drug Administration 
5600 Fishers Lane 
Rockville, MD 20857 
Pediatric Tetracycline Use 
Reports of adverse reactions in children given 
tetracycline liquid and tetracycline liquid congeners con­
tinue to be of concern to health professionals. 
When pediatric tetracycline drops were withdrawn 
from the market in 1978, other liquid forms were allowed 
to remain, primarily because they were needed for 
geriatric patients (see May-July 1978 Drug Bulletin). 
However, the figures from the July 1978 - June 1979 
National Disease and Therapeutic Index show that 60 
percent of the prescriptions for tetracycline liquid are 
written for children from 0 to 9 years old, while geriatric 
patients over age 65 account for only 6 percent of the 
prescriptions. Similarly, 80 percent of the prescriptions 
for tetracycline congener liquid are written for children 
under the age of 9. 
Tetracycline liquid and tetracycline congeners liquid 
may cause depression of bone growth and permanent dis­
coloration of the teeth, as well as enamel hypoplasia, 
when given during tooth development (last half of preg­
nancy, infancy, and childhood to the age of 8 years). 
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Therefore, tetracycline should not be used in this age 
group unless other drugs are not likely to be effective or 
are contraindicated. 
Tetracycline congeners include: oxytetracycline (Ter-
ramycin), chlortetracycline (Aureomycin), 
demeclocycline (Declomycin), doxycycline (Doxy-II, 
Vibramycin), methacycline (Rondomycin), and 
minocycline (Minocin, Vectrin). 
Medical Device and Laboratory 
Product Problem Reporting Program 
(PRP) 
Health care professionals can now dial a toll-free 
WATS number to report problems that they experience 
with medical devices and in vitro diagnostic products. 
The number is (800) 638-6725 (in Maryland, call collect 
(301) 881-0256). Callers should be ready to furnish the in­
formation requested on the tear-out reporting form in 
this Drug Bulletin. 
FDA encourages the health care community to report: 
® hazardous or potentially hazardous products 
• improper labeling 
® incomplete or confusing instructions 
9 erroneous information 
• designs that encourage human error 
• performance failures 
© non-sterile products 
• packaging errors 
9 defective components 
® other situations that could affect the safety and 
efficacy of a device. 
FDA's problem reporting program covers only prod­
uct-related defects, and information concerning patients 
is not requested. 
Device and diagnostic problem reports help FDA de­
termine when a product poses an actual or potential 
hazard to health, which sometimes results in a recall. The 
Agency also uses this information to detect recurring 
problems, and to become aware of device deficiencies. 
These data are also useful in developing profiles, perfor­
mance standards, and detecting trends of manufacturer/ 
product problems. 
FDA piloted the problem reporting program in 1973 to 
collect data on problems in clinical laboratories. The 
U.S. Pharmacopeia operates this program under contract 
with FDA's Bureau of Medical Devices. 
Infant Formulas 
Over the past several months, infant formulas have 
been involved in an increasing number of health-related 
problems. Ranging from nutrient deficiencies to process­
ing breakdowns, these events have served to focus atten­
tion on procedures necessary to assure the quality and 
safety of these products. 
FDA advises that all hospitals and other health 
facilities immediately begin to evaluate their procedures 
for storage, distribution, and preparation of infant for­
mulas to identify possible points of contamination and/or 
reduction in nutritive value. 
In addition, FDA needs to have more information on 
infant illnesses in which formulas may be implicated. The 
Agency-would welcome information on the clinical 
nature of such illnesses, any supportive laboratory find­
ings, the product or products that may be involved, the 
time that the problem occurred, and the length of time 
the formula was used. This information should be sent to 
FDA's Bureau of Foods, HFF-1, 200 C Street, S.W., 
Washington, D.C. 20204. 
FDA is reevaluating its procedures for assuring the 
quality and nutritional efficacy of infant formulas. The 
Agency is considering the establishment of standards for 
nutritional quality, as well as development of procedures 
for requiring premarket clearance of such formulas. 
FDA also is considering the establishment of required 
quality assurance checks as part of good manufacturing 
practice for each such product. Early in 1980, FDA will 
hold the first of a series of international conferences to 
determine which nutrients need to be checked routinely 
and which nutrients need to be evaluated only under 
special conditions. In addition, these conferences will ex­
plore the scientific basis for construction of these stand­
ards. 
ERRATA 
"Update on Amphetamine Abuse and Labeling" in 
the September 1979 Drug Bulletin (Volume 9, Number 4) 
incorrectly identified phenmetrazine as a Schedule III 
drug. Phenmetrazine is a Schedule II drug. The anorec­
tic phendimetrazine, however, is a Schedule III drug. 
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After completing the form on the other side 
of this sheet, 
Please tear off the page, triple fold, and 
staple or seal with tape; 
No postage is necessary. 
The Agency appreciates receiving this type of 
input from physicians and other health profes­
sionals. 
MEDICAL DEVICE AND LABORATORY PRODUCT 
PROBLEM REPORTING PROGRAM 
Form Approved; OMB No. 57-R0059 — —«_ 
ACCESS 
DATE 
1 TRADE NAME AND TYPE OF PRODUCT (Attach labeling, it available) 
2 PRODUCT IDENTIFICATION 
LOT NO SERIAL NO PRODUCT NO 
3 NAME AND ADDRESS OF MANUFACTURER 
4 EXPIRATION DATE (It applicable) 
5 YOUR NAME 
6 YOUR FACILITY S NAME. ADDRESS. AND ZIP CODE 
AREA CODE AND PHONE NUMBER OF YOUR FACILITY 
7 PROBLEMS NOTED OR SUSPECTED 
RETURN TO 
United States Pharmacopeia 
12601 Twinbrook Parkway 
Rockville, Maryland 20852 
Attention: Dr. Joseph G. Valentino 
OR CALL TOLL FREE ANYTIME 
800-638-6725* 
IN THE CONTINENTAL UNITED STATES 
•In Maryland, call collect (301)881-0256 
between 9:00 AM and 4:30 PM 
PRAIRIE VIEW A&M UNIVERSITY 
PRAIRIE VIEW, TEXAS 77445 
October 22# 1979 
Office of 
THE PRESIDENT 
Dr. E. R. Owens 
Medical Director 
Owens-Franklin Health Center 
Prairie View A&M University 
Prairie View, IX 77445 
Dear Dr. Owensi 
I received a copy of a letter fran Dr. Jones to Mrs. Pierre 
cxancerning continued misunderstandings at the Owens-Franklin Health 
Center. 
As Director of the Health Center, 1 am asking you to issue a 
directive to the nurses relating to patient-doctor care. I am aslo 
asking you to issue a directive to Mrs. Pierre concerning patient-
doctor care. Please monitor the directive to see that every one 
complies accordingly. 
I am sure this course of action will taring the matter pointed 
out in Dr. Jones' letter to a successful conclusion. If it does 
not# please let rae know. 
Very truly yours 
Alvin I. Thomas 
President 
AIT/rr 
cc: Mrs. Theloa Pierre 
Dr. Jesae Jones 
"AN EQUAL OPPORTUNITY EMPLOYER' 
PRAIRIE VIEW A&M UNIVERSITY 
PRAIRIE VIEW, TEXAS 77445 
September 12, 1979 
0, 
STUDENT FINANCIAL AID CENTER 
I 
SEP 1 3 191 
Dr. E. R. Owens 
Medical Director 
Ownes-Franklin Health Center 
Prairie View A&M University 
Prairie View,TX 77445 






Recently this office requested that you complete and submit a student employ­
ment form indicating the positions available in your department, a brief job 
description, number needed, and hours required. 
As of this date you have failed to return the request to the Student Empolyment 
Office. 
I am enclosing another request form which you should complete and return to 
the Student Employment Office by Monday, September 17, 1979. Your payroll for 
the month of September will not be accepted unless the request form is on file. 
Sincerely, 
A. D. James, Jr., Director 
Student Financial Aid 
ADJJ/wes 
Enclosure 
cc: Dr. A. I. Thomas 
Mr. G. W. Kendrick 
Mr. F. C. Yepp 
AN EQUAL OPPORTUNITY EMPLOYER" 
